Cardiac arrhythmias affect millions across the world and are responsible for a fifth of all deaths in the Netherlands.

My name is Daniel Meyer, VP and head of investor relations. Our earnings press release and investor spreadsheet is now ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

Cardiac arrhythmias affect millions across the world and are responsible for a fifth of all deaths in the Netherlands.

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...

Researchers have identified a gene therapy that could prevent life-threatening arrhythmias by restoring the heart’s ...

The Procter & Gamble Company ( NYSE: PG) Consumer Analyst Group of New York Conference Call February 20, 2025 9:00 AM ET Andre Schulten - Chief Financial Officer John Chevalier - Senior Vice President ...

A venture capital (VC) revolution in advanced analytics and artificial intelligence (AI) is advancing an industry ...

Paris, France, February 20, 2025 – EG 427, a biotechnology company leading the development of pinpoint genetic medicines for prevalent chronic diseases in neurology, announced today the successful ...